Lung cancer in Brazil: epidemiology and treatment challenges

Sá, Vanessa Karen de; Coelho, Juliano Cé; Capelozzi, Vera Luíza; Azevedo, Sérgio Jobim

doi:10.2147/lctt.s93604

Cited by 22 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer is a major public health problem, being the second-leading global cause of death after cardiovascular diseases [ 1 , 2 ]. According to the American Cancer Society, there was an overall estimate of 1,685,210 new cancer cases diagnosed in United States and approximately 600,000 deaths in 2016 [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

A Comparative Evaluation of the Cytotoxic and Antioxidant Activity of Mentha crispa Essential Oil, Its Major Constituent Rotundifolone, and Analogues on Human Glioblastoma

Türkez

Tozlu

Lima

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Cancer is a major public health problem around the globe. This disorder is affected by alterations in multiple physiological processes, and oxidative stress has been etiologically implicated in its pathogenesis. Glioblastoma (GBM) is considered the most common and aggressive brain tumor with poor prognosis despite recent improvements in surgical, radiation, and chemotherapy-based treatment approaches. The purpose of this study was to evaluate antitumor activity from Mentha crispa essential oil (MCEO), its major constituent rotundifolone (ROT), and a series of six analogues on the human U87MG glioblastoma cell line. Cytotoxic effects of the compounds on the human U87MG-GBM cell line were assessed using in vitro cell viability and oxidative and molecular genetic assays. In addition, biosafety assessment tests were performed on cultured human blood cells. Our findings revealed that MCEO, 1,2-perillaldehyde epoxide (EPER1), and perillaldehyde (PALD) were the most cytotoxic compounds against U87MG cells, with IC50 values of 16.263, 15.087, and 14.888 μg/mL, respectively. Further, these compounds increased the expressions of BRAF, EGFR, KRAS, NFκB1, NFκB1A, NFκB2, PIK3CA, PIK3R, PTEN, and TP53 genes at different degrees and decreased the expression of some genes such as AKT1, AKT2, FOS, and RAF1. Finally, treatment with MCEO, EPER1, and PALD did not lead to genotoxic damage in blood cells. Taken together, our findings reveal antiproliferative potential of MCEO, its major component ROT, and its tested analogues. Some of these chemical analogues may be useful as prototypes for the development of novel chemotherapeutic agents for treating human brain cancer and/or other cancers due to their promising activities as well as nonmutagenic property and safety.

show abstract

Section: Introductionmentioning

confidence: 99%

A Comparative Evaluation of the Cytotoxic and Antioxidant Activity of Mentha crispa Essential Oil, Its Major Constituent Rotundifolone, and Analogues on Human Glioblastoma

Türkez

Tozlu

Lima

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The probability of cure for patients with lung cancer is directly related to the ability to detect the disease in early stages, when both surgical and chemotherapy are more effective. Therefore, early detection is crucial, particularly in patients at high risk, like smokers 2,3,17 .…”

Section: Discussionmentioning

confidence: 99%

“…Smoking itself increases the risk of lung cancer 5 to 10 times, presenting a significant doseresponse relationship. Not only active smoking, but also passive smoking is a risk factor for lung cancer, and exposure to tobacco accounts for about 20% of cases in nonsmokers 3,6,[8][9][10] .…”

Section: Epidemiology Of Lung Cancermentioning

confidence: 99%

Serum biomarkers for lung cancer screening

Aquino

Guedes

Pires

et al. 2019

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Lung cancer is by far the leading cause of cancer death among both men and women. Screening patients at high risk of developing lung cancer is a worldwide priority, since it can be cured if diagnosed in early stages. Currently, screening in high risk individuals is made using low dose computed tomography, however, this method may lead to false-positive tests and overdiagnosis. The usefulness of serum biomarkers would be relevant in two situations: 1) the screening of large groups at high risk of developing lung cancer, where the biomarker should be very sensitive and 2) during the investigation of pulmonary nodules, where the biomarker should be very specific. Several serum biomarkers have been tested to work as biomarkers for lung cancer screening. Unfortunately, so far, none of them has come into current clinical practice. In this review, we analyze some of the serum biomarkers described in the last 10 years, evaluating their potential as tools to detect lung cancer, particularly in smokers. The use of serum biomarkers and imaging methods together seems to be a solution to early diagnosis of lung cancer, more efficient treatment and enhanced chance of cure.

show abstract

“…Em relação à mutação do KRAS, a taxa de pacientes positivos é maior em comparação com a literatura (Bacchi et al, 2012;Carneiro et al, 2014;de Melo et al, 2015;Arrieta et al, 2015), provavelmente devido ao número reduzido de pacientes testados neste estudo (n = 9 Melo et al, 2015), mas menor que na Coreia do Sul e em Taiwan (de Castro et al, 2017). Os regimes baseados em platina foram a prática clínica mais comum como terapia de primeira linha (83,6%), conforme recomendado pelas diretrizes nacionais e internacionais (NCCN, 2017;de Sa et al, 2016) e também foram o tratamento predominante nos estudos de dados do mundo real publicados na Ásia-Pacífico, América do Norte e Europa (de Castro et al, 2017;Davis et al, 2015;Sacher et al, 2015;Solem et al, 2015a;Davies et al, 2017). No tratamento de segunda linha, a estratégia de agente único (52,0%) foi a mais comum, seguida pelos regimes contendo platina (23,7%) e inibidores da tirosina quinase (TKi) (19,1%), também de acordo com as recomendações das diretrizes (NCCN, 2017;de Sa et al, 2016).…”

Section: Discussionunclassified

“…Os regimes baseados em platina foram a prática clínica mais comum como terapia de primeira linha (83,6%), conforme recomendado pelas diretrizes nacionais e internacionais (NCCN, 2017;de Sa et al, 2016) e também foram o tratamento predominante nos estudos de dados do mundo real publicados na Ásia-Pacífico, América do Norte e Europa (de Castro et al, 2017;Davis et al, 2015;Sacher et al, 2015;Solem et al, 2015a;Davies et al, 2017). No tratamento de segunda linha, a estratégia de agente único (52,0%) foi a mais comum, seguida pelos regimes contendo platina (23,7%) e inibidores da tirosina quinase (TKi) (19,1%), também de acordo com as recomendações das diretrizes (NCCN, 2017;de Sa et al, 2016). As estratégias de agente único e TKi na segunda linha também corroboram dados de outros estudos de dados do mundo real na Europa (de Castro et al, 2017;de Marinis et al, 2014;Gridelli et al, 2014;Bischoff et al, 2010 Vergnenegre et al, 2012;Carpentier et al, 2015;Zietemann et al, 2011;Zietemann et al, 2010;Reinmuth et al, 2013;Gridelli et al, 2011), Canadá (Sacher et al, 2015), Estados Unidos (Davis et al, 2015;Pan et al, 2013), Brasil (Younes et al, 1992;de Castro et al, 2017;Lopes et al, 2015) e Ásia-Pacífico (de Castro et al, 2017).…”

Section: Discussionunclassified

Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em instituições brasileiras privadas

Baldotto¹,

Julian²,

Mascarenhas³

et al. 2018

JBES

View full text Add to dashboard Cite

RESUMOObjetivo: No Brasil, dados clínicos e custos econômicos do câncer de pulmão de não pequenas células (CPNPC) são escassos. Portanto, conduzimos este estudo para coletar dados de mundo real sobre padrões de tratamento e uso de recursos para CPNPC avançado ( CPNPCa) em pacientes em instituições privadas brasileiras. Métodos: Coletamos dados de prontuários de seis instituições privadas no Brasil. Os pacientes elegíveis tinham diagnóstico de CPNPC avançado ou recorrente (estágios IIIB e IV) entre janeiro de 2011 e julho de 2014, e haviam recebido pelo menos duas linhas de quimioterapia. Dados foram resumidos usando estatísticas descritivas e os custos foram estimados pela abordagem bottom-up. Resultados: Dos 430 pacientes selecionados, 152 foram elegíveis para coleta de dados. A idade mediana dos pacientes foi de 62 anos e 55,9% eram do sexo masculino. Entre os pacientes, 57,2% e 31,6% receberam três e quatro linhas de tratamento, respectivamente. Dezesseis e vinte regimes foram utilizados como tratamentos de primeira e segunda linha. Bevacizumabe + carboplatina + paclitaxel (n = 32; 21,1%) foi o mais frequente na primeira linha, enquanto docetaxel isolado (n = 36; 23,7%) foi o regime mais comum de segunda linha. Hospitalizações e visitas ao pronto-socorro foram registradas em 52% e 25% dos pacientes, respectivamente. O custo total da coorte foi de R$ 47. 692.195,1 (US$ 14.803.425,4). Conclusões: Os padrões de tratamento para pacientes com CPNPCa em instituições privadas brasileiras são heterogêneos. O alto uso e custos de recursos observados entre os pacientes da CPNPCa têm um impacto econômico significativo para o sistema de saúde privado brasileiro. ABSTRACTObjective: In Brazil, data on clinical and economic burden of non-small cell lung cancer (NSCLC) are scarce. Therefore, we conducted this study to gather real-world data on treatment patterns and resource use for advanced NSCLC (aNSCLC) patients in Brazilian private institutions. Methods: We collected data from medical charts from six private institutions in Brazil. Eligible patients were diagnosed with advanced or recurrent NSCLC (stages IIIB and IV) between January 2011 and July 2014, and had received at least two lines of chemotherapy. Data were summarized using descriptive statistics and costs estimated by bottom-up approach. Results: Out of 430 charts screened, 152 were eligible for data collection. Patients' median age was 62 years, 55.9% were male. Among patients, 57.2% são funcionários da Kantar Health. Os demais autores declaram não ter conflitos de interesse relevantes para a submissão do manuscrito. Este estudo foi patrocinado pela Bristol-Myers Squibb.Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em instituições brasileiras privadas Treatment patterns, resource use and cost-of-illness of advanced non-small lung cancer in Brazilian private institutions J Bras Econ Saúde 2018;10(2): 86-106Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em ins...

show abstract

Lung cancer in Brazil: epidemiology and treatment challenges

Cited by 22 publications

References 49 publications

A Comparative Evaluation of the Cytotoxic and Antioxidant Activity of Mentha crispa Essential Oil, Its Major Constituent Rotundifolone, and Analogues on Human Glioblastoma

A Comparative Evaluation of the Cytotoxic and Antioxidant Activity of Mentha crispa Essential Oil, Its Major Constituent Rotundifolone, and Analogues on Human Glioblastoma

Serum biomarkers for lung cancer screening

Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em instituições brasileiras privadas

Contact Info

Product

Resources

About